Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | MEN1 | O00255 | 7/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.48 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8374386 | 0.89 | MEN1 (0.64) | LMNASMN1; SMN2MAPTMEN1KMT2A | |
| SCHEMBL27484718 | 0.87 | POLB (0.55) | SMN1; SMN2MAPTMEN1KMT2APOLB | |
| SCHEMBL8380032 | 0.87 | POLB (0.69) | LMNASMN1; SMN2MAPTMEN1KMT2A | |
| SCHEMBL711162 | 0.84 | SMN1; SMN2 (0.58) | LMNASMN1; SMN2MAPTMEN1KMT2A | |
| SCHEMBL5627879 | 0.84 | MEN1 (0.53) | SMN1; SMN2MAPTMEN1KMT2APOLB | |
| SCHEMBL7335938 | 0.84 | SMN1; SMN2 (0.69) | LMNASMN1; SMN2MAPTMEN1KMT2A | |
| SCHEMBL7833515 | 0.84 | SMN1; SMN2 (0.69) | LMNASMN1; SMN2MAPTMEN1KMT2A | |
| Methyl 3,5-Dinitrobenzoate SCHEMBL418416 | 0.84 | SMN1; SMN2 (0.60) | SMN1; SMN2MAPTMEN1KMT2APOLB | |
| SCHEMBL561284 | 0.84 | HTT (0.64) | LMNASMN1; SMN2MAPTMEN1KMT2A | |
| SCHEMBL10193010 | 0.82 | HTT (0.51) | SMN1; SMN2MAPTMEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124617-B2 | Imidazopyridine compounds | TAKEDA SAN DIEGO, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-8124617-B2 | Imidazopyridine compounds | TAKEDA SAN DIEGO, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-8124617-B2 | Imidazopyridine compounds | TAKEDA SAN DIEGO, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-20100069431-A1 | IMIDAZOPYRIDINE COMPOUNDS | TAKEDA SAN DIEGO, INC. | 2010-03-18 | — | — | US | disclosed |
| US-20100069431-A1 | IMIDAZOPYRIDINE COMPOUNDS | TAKEDA SAN DIEGO, INC. | 2010-03-18 | — | — | US | disclosed |
| US-20100069431-A1 | IMIDAZOPYRIDINE COMPOUNDS | TAKEDA SAN DIEGO, INC. | 2010-03-18 | — | — | US | disclosed |
| EP-1940837-A2 | IMIDAZOPYRIDINE COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007028135-A2 | IMIDAZOPYRIDINE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069431-A1 | IMIDAZOPYRIDINE COMPOUNDS | GCK, GCKR, KHK | LMNA 4158/4885SMN1; SMN2 3631/4885MAPT 3003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.